Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress

Author's Avatar
May 31, 2023

Akili%2C+Inc. (Nasdaq: AKLI), a leading digital medicine company, is presenting pivotal trial data on EndeavorRx® (AKL-T01) in adolescents with attention-deficit/hyperactivity disorder (ADHD) at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami Beach on May 31, 2023, and at the Elevate Psych Congress in Las Vegas on June 2-3, 2023. The poster presentations highlight results of Akili’s STARS-ADHD-Adolescents label expansion trial evaluating the efficacy and safety of EndeavorRx in adolescents ages 13-17 with ADHD.